Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07467213 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction

Study acronym: PCAB-AMI
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Phase changed: Phase 4 → Phase 3
    • Recruitment opened
    • Start date changed from estimate of Apr 1, 2026 to Jun 23, 2026
    • Eligibility criteria shortened, about 7 words
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to compare the clinical outcomes between routine use of potassium competitive acid blocker (P-CAB) and guideline-directed gastrointestinal (GI) protection strategy in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) and being treated with dual antiplatelet therapy (DAPT).
Trial Details
NCT Number NCT07467213
Lead Sponsor Samsung Medical Center
Conditions
(from sponsor)		 Acute Myocardial Infarction (AMI), Gastrointestinal Bleeding
Related terms Gastrointestinal Hemorrhage
Enrollment 5,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov